Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly plans to buy privately held ⁠Merida Biosciences for ‌up to $2.88 billion in cash.

发布方
CNBC
发布时间
篇幅
107 字 · 1 分钟
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly ​said on Monday it would buy privately held Merida Biosciences for up to $2.88 billion in cash, as it seeks to expand its pipeline of potential treatments for immunity-related and allergic diseases.

Lilly has been on an acquisition spree, boosted by the booming demand for its obesity drugs. Its deal spending in 2026 has outpaced that in the prior years.

Merida is developing medicines to selectively target antibodies that cause a range of immunity-related conditions.

Its lead drug candidate, MER511, is in the early stage of development for autoimmune disorders such as Graves' disease and thyroid eye disease.

This story is developing. Please check back for updates.

内容来源

本文由CNBC于2026年8月31日首次发布。HUE Legacy Ventures 并非本文作者。

Carried in full with attribution and a link to the original. Rights remain with the publisher, who may request removal at any time.

在 cnbc.com 阅读 →